Quest Diagnostics Inc. Files Definitive Proxy Statement for 2024 Annual Meeting

Ticker: DGX · Form: DEF 14A · Filed: Apr 5, 2024 · CIK: 1022079

Quest Diagnostics Inc DEF 14A Filing Summary
FieldDetail
CompanyQuest Diagnostics Inc (DGX)
Form TypeDEF 14A
Filed DateApr 5, 2024
Risk Level
Pages15
Reading Time18 min
Key Dollar Amounts$9.03 billion, $7.49, $8.71, $0.71, $0.75
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Quest Diagnostics, Healthcare, Diagnostics

TL;DR

<b>Quest Diagnostics' 2024 Proxy Statement details the upcoming Annual Meeting and outlines the company's mission, strategy, and values.</b>

AI Summary

QUEST DIAGNOSTICS INC (DGX) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Quest Diagnostics Incorporated filed a Definitive Proxy Statement (DEF 14A) on April 5, 2024. The filing announces the 2024 Annual Meeting of Stockholders to be held on May 16, 2024, at 10:30 a.m. Eastern Time in Clifton, New Jersey. The company's purpose is 'Working together to create a healthier world, one life at a time'. Key strategies include collaborating with healthcare providers, offering a broad testing menu, leveraging data for population health, and improving quality/efficiency with AI and automation. The company serves a diverse range of clients including physicians, hospitals, patients, health plans, employers, and pharmaceutical companies.

Why It Matters

For investors and stakeholders tracking QUEST DIAGNOSTICS INC, this filing contains several important signals. This filing provides shareholders with crucial information regarding the upcoming annual meeting, including voting matters and the company's strategic direction. Understanding Quest Diagnostics' stated purpose, strategy (including AI and automation), and customer base is essential for investors to assess the company's future performance and competitive positioning.

Risk Assessment

Risk Level: — QUEST DIAGNOSTICS INC shows moderate risk based on this filing. The filing is a routine proxy statement and does not contain new financial performance data or strategic shifts that would indicate immediate high risk.

Analyst Insight

Review the proposals to be voted on at the Annual Meeting and the company's strategic priorities, particularly those involving AI and automation, to inform investment decisions.

Key Numbers

  • 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
  • May 16 — Meeting Date (May 16, 2024)
  • 10:30 a.m. Eastern Time — Meeting Time (10:30 a.m. Eastern Time)

Key Players & Entities

  • Quest Diagnostics Incorporated (company) — Registrant
  • 2024 Annual Meeting of Stockholders (event) — Meeting to be held
  • May 16, 2024 (date) — Date of Annual Meeting
  • Clifton, New Jersey (location) — Location of Annual Meeting
  • April 5, 2024 (date) — Filing Date
  • AI (technology) — Mentioned in strategy

FAQ

When did QUEST DIAGNOSTICS INC file this DEF 14A?

QUEST DIAGNOSTICS INC filed this Proxy Statement (DEF 14A) with the SEC on April 5, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by QUEST DIAGNOSTICS INC (DGX).

Where can I read the original DEF 14A filing from QUEST DIAGNOSTICS INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by QUEST DIAGNOSTICS INC.

What are the key takeaways from QUEST DIAGNOSTICS INC's DEF 14A?

QUEST DIAGNOSTICS INC filed this DEF 14A on April 5, 2024. Key takeaways: Quest Diagnostics Incorporated filed a Definitive Proxy Statement (DEF 14A) on April 5, 2024.. The filing announces the 2024 Annual Meeting of Stockholders to be held on May 16, 2024, at 10:30 a.m. Eastern Time in Clifton, New Jersey.. The company's purpose is 'Working together to create a healthier world, one life at a time'..

Is QUEST DIAGNOSTICS INC a risky investment based on this filing?

Based on this DEF 14A, QUEST DIAGNOSTICS INC presents a moderate-risk profile. The filing is a routine proxy statement and does not contain new financial performance data or strategic shifts that would indicate immediate high risk.

What should investors do after reading QUEST DIAGNOSTICS INC's DEF 14A?

Review the proposals to be voted on at the Annual Meeting and the company's strategic priorities, particularly those involving AI and automation, to inform investment decisions. The overall sentiment from this filing is neutral.

How does QUEST DIAGNOSTICS INC compare to its industry peers?

Quest Diagnostics operates in the medical laboratories industry, providing diagnostic testing and related services.

Are there regulatory concerns for QUEST DIAGNOSTICS INC?

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs proxy solicitations.

Industry Context

Quest Diagnostics operates in the medical laboratories industry, providing diagnostic testing and related services.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs proxy solicitations.

What Investors Should Do

  1. Review the agenda and proposals for the 2024 Annual Meeting of Stockholders.
  2. Analyze the company's stated purpose and strategic initiatives, including the role of AI and automation.
  3. Assess the company's customer base and market reach as described in the filing.

Key Dates

  • 2024-05-16: 2024 Annual Meeting of Stockholders — Key date for shareholder voting and company updates.
  • 2024-04-05: Filing Date of Definitive Proxy Statement — Indicates the official release of proxy materials to shareholders.

Glossary

DEF 14A
Definitive Proxy Statement (Standard SEC filing for proxy solicitations, providing detailed information to shareholders.)
Proxy Statement
A document required by the SEC that provides shareholders with information about matters to be voted on at a company's annual meeting. (Essential for shareholders to make informed voting decisions.)

Year-Over-Year Comparison

This is the initial filing of the 2024 Definitive Proxy Statement, so no comparison to a prior filing is available within this document.

Filing Stats: 4,387 words · 18 min read · ~15 pages · Grade level 13.2 · Accepted 2024-04-05 16:33:12

Key Financial Figures

  • $9.03 billion — g COVID-19 testing) revenues by 7.1% to $9.03 billion. We generated diluted earnings per sh
  • $7.49 — d diluted earnings per share ("EPS") of $7.49 and adjusted diluted EPS of $8.71. Ou
  • $8.71 — ") of $7.49 and adjusted diluted EPS of $8.71. Our strong relationships with health
  • $0.71 — he dividend by approximately 5.6%, from $0.71 per share of common stock to $0.75 per
  • $0.75 — from $0.71 per share of common stock to $0.75 per share of common stock. We repurch
  • $276 million — n stock. We repurchased approximately $276 million of our common stock in 2023. Through
  • $10.5 billion — of 2012 we have returned approximately $10.5 billion to stockholders: $7.5 billion through c
  • $7.5 billion — ximately $10.5 billion to stockholders: $7.5 billion through common stock repurchases (inclu
  • $1.8 billion — ugh common stock repurchases (including $1.8 billion associated with pre-tax proceeds from d
  • $3.0 billion — re-tax proceeds from divestitures), and $3.0 billion through common stock dividends. 2024
  • $17 billion — nual revenues nearly five-fold to reach $17 billion in 2012, and expanding in Asia and othe

Filing Documents

Executive Compensation

Executive Compensation 30 Pay Components 31 Base Salary 31 Annual Cash Incentive Compensation 32 Long-Term Incentive Awards 36 2024 Actions 40 Other 41 Risk Assessment 42 Share 42 Policies Regarding Hedging or Pledging our Common Stock 42 Compensation and Leadership Development Committee Report 43 2023 Summary Compensation Table 43 2023 Grants of Plan-Based Awards Table 44 Additional Information Regarding 2023 Summary Compensation and Grants of Plan-Based Awards Tables 45 Outstanding Equity Awards at 2023 Fiscal Year-End 46 2023 Option Exercises and Stock Vested Table 47 2023 Nonqualified Deferred Compensation Table 47 2023 Potential Payments Upon Termination or Change in Control 48 Pay Ratio 51 Equity Compensation Plan Information 52 Pay Versus Performance 53 Description of Pay Versus Performance Relationships 58 Audit 61 Proposal No. 3—Ratification of Appointment of Independent Registered Public Accounting Firm 61 Pre-Approval of Audit and Permissible Non-Audit Services 62 Fees and Services of PwC 62 Audit and Finance Committee Report 63 Additional Action Items 64 Proposal No. 4—Amending our Restated Certificate of Incorporation to Provide for the Exculpation of Officers as Permitted by Law 64 Proposal No. 5—Stockholder Proposal Regarding Managing Climate Risk Through Science-Based Targets and Transition Planning 66 Frequently Asked Questions 69 Annex A Reconciliation of Non-GAAP and GAAP Information A-1 Annex B Performance Share Units and Annual Incentive Compensation Payouts B-1 Annex C Proposed Amendment to Paragraph 11(a) of Restated Certificate of Incorporation C-1 2024 Proxy Statement INFORMATION ABOUT OUR CORPORATE GOVERNANCE Proposal No. 1 — Election of Directors The Board of Directors recommends that you vote FOR each of the nominees described below Our Board currently has ten directors. Directors are elected ann

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.